COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.

Simple item page
dc.contributor.authorBright, Bisi
dc.contributor.authorBabalola, Chinedum Peace
dc.contributor.authorSam-Agudu, Nadia Adjoa
dc.contributor.authorOnyeaghala, Augustine Anayochukwu
dc.contributor.authorOlatunji, Adebola
dc.contributor.authorAduh, Ufuoma
dc.contributor.authorSobande, Patrick O
dc.contributor.authorCrowell, Trevor A
dc.contributor.authorTebeje, Yenew Kebede
dc.contributor.authorPhillip, Sunny
dc.contributor.authorNdembi, Nicaise
dc.contributor.authorFolayan, Morenike Oluwatoyin
dc.date.accessioned2024-09-26T08:41:15Z
dc.date.available2024-09-26T08:41:15Z
dc.date.issued2021-03-03T00:00:00Z
dc.description14p
dc.description.abstractThe COVID-19 pandemic is a biosecurity threat, and many resource-rich countries are stockpiling and/or making plans to secure supplies of vaccine, therapeutics, and diagnostics for their citizens. We review the products that are being investigated for the prevention, diagnosis, and treatment of COVID-19; discuss the challenges that countries in sub-Saharan Africa may face with access to COVID-19 vaccine, therapeutics, and diagnostics due to the limited capacity to manufacture them in Africa; and make recommendations on actions to mitigate these challenges and ensure health security in sub-Saharan Africa during this unprecedented pandemic and future public-health crises. Sub-Saharan Africa will not be self-reliant for COVID-19 vaccines when they are developed. It can,however, take advantage of existing initiatives aimed at supporting COVID-19 vaccine access to resource-limited settings such as partnership with AstraZeneca, the Coalition for Epidemic Preparedness and Innovation, the Global Alliance for Vaccine and Immunisation, the Serum Institute of India, and the World Health Organization’s COVID-19. Technology Access Pool. Accessing effective COVID-19 therapeutics will also be a major challenge for countries in sub-Saharan Africa, as production of therapeutics is frequently geared towards profitable Western markets and is ill-adapted to sub-Saharan Africa realities. The region can benefit from pooled procurement of COVID-19 therapy by the Africa Centres for Disease Control and Prevention in partnership with the African Union. If the use of convalescent plasma for the treatment of patients who are severely ill is found to be effective, access to the product will be minimally challenging since the region has a pool of recovered patients and human resources thatcan man supportive laboratories. The region also needs to drive the local development of rapid-test kits and other diagnostics for COVID-19.
dc.identifier.citationBright, B., Babalola, C. P., Sam-Agudu, N. A., Onyeaghala, A. A., Olatunji, A., Aduh, U., ... & Folayan, M. O. (2021). COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. Globalization and health, 17, 1-14.
dc.identifier.other33658050
dc.identifier.urihttps://ir.oauife.edu.ng/handle/123456789/6616
dc.language.isoen
dc.publisherBiomedical Central
dc.subjectCOVID-19
dc.subjectDiagnostics
dc.subjectManufacturing capability
dc.subjectSub-Saharan Africa
dc.subjectTherapeutics
dc.subjectVaccine
dc.titleCOVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa.
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
COVID 19 preparedness_capacity to manufacture vaccines, therapeutics and diagnostics.pdf
Size:
704.83 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Department of Child Dental Health- Journal Articles